Dr Gyawali speaks with ecancer reporter Will Davies about highlights from ESMO 2017.
Throughout, Dr Gyawali keeps patient-centric endpoints including quality of life and overall survival as the focus, noting the promise of many trials in extending progression free survival and response, but cautioning that this may not translate to longer, better lives for patients.
Part 2 of his round up, covering results from headline trials including MONARCH 3, PACIFIC and FLAURA, is available here.
For more on STAMPEDE data with Matthew Sydes, click here.
For more on the RANGE trial with Dr Daniel Petrylak, click here.
For more on the Checkmate 214 trial of immunotherapies in mRCC, click here.
For more on COMBI-AD and Checkmate 238 in melanoma, watch the panel comments from the press session here.
For more on the duration of treatment in colorectal cancer, click here.